Table 2 Patient characteristics of the four patient groups, representing control group: patients without NET diagnosis based on PET/CT, group 1: primary tumors solely or with a few (≤ 2) metastases (limited disease), group 2: liver-only metastases and group 3: extensive metastases

Male

22 (54%)

4 (40%)

2 (50%)

8 (32%)

 < 0.001

20 (44%)

10 (48%)

3 (43%)

15 (48%)

 < 0.001

Female

19 (46%)

6 (60%)

2 (50%)

17 (68%)

25 (56%)

11 (52%)

4 (57%)

16 (52%)

Age (years)

56 ± 14 (22–79)

64 ± 9 (46–75)

57 ± 12 (48–75)

62 ± 13 (39–84)

0.200

59 ± 12 (27–84)

65 ± 9.83 (47–80)

57 ± 9.81 (44–67)

61 ± 11.7 (40–82)

0.282

Weight (kg)

81.1 ± 18.4 (53–120)

77.6 ± 14.2 (60–104)

88.3 ± 13.0 (73–103)

75.7 ± 15.0 (53–117)

0.415

87.6 ± 22.3 (40–145)

73.5 ± 16.1 (44–113)

78.6 ± 18.1 (52–102)

69.6 ± 10.6 (51–100)

0.001

Height (cm)

176 ± 11.3 (155–196)

169 ± 6.72 (158–180)

174 ± 9.29 (164–182)

171 ± 7.94 (157–185)

0.270

173 ± 10.2 (154–193)

171 ± 8.30 (160–186)

174 ± 11.3 (159–185)

174 ± 7.70 (158–192)

0.871

GFR (Cockcroft Gault, mL/min)

94.8 ± 31.5 (49.6–160)

101 ± 31.5 (47.4–146)

99.6 ± 10.2 (93.4–115)

85.3 ± 26.5 (33.8–124)

0.482

115 ± 42.5 (41.7–190)

84.0 ± 21.5 (50.3–117)

93.0 ± 49.1 (41.3–183)

79.3 ± 20.4 (35.8–123)

0.107

Peptide amount administered (µg)

12.5 ± 2.65 (8.05–16.9)

13.1 ± 1.45 (10.6–15.7)

14.5 ± 1.08 (13.4–16.0)

12.8 ± 2.48 (7.16–16.6)

0.465

6.13 ± 2.29 (2.49–11.2)

5.22 ± 1.58 (2.43–7.78)

6.74 ± 2.72 (3.31–11.1)

6.47 ± 2.44 (3.37–11.0)

0.204

Radioactivity administered (MBq)

91.7 ± 23.4 (43.4–130)

79.7 ± 14.2 (57.8–101)

83.7 ± 15.3 (64.7–99.6)

88.5 ± 16.6 (50.3–133)

0.378

89.5 ± 11.4 (66.0–110)

84.9 ± 14.2 (60.1–106)

85.8 ± 12.0 (69.0–105)

86.2 ± 14.8 (43.8–106)

0.513

Injection-acquisition interval (min)

48 ± 11 (35–78)

43 ± 7 (34 -55)

43 ± 2 (41–45)

44 ± 6 (35–55)

0.153

45 ± 6 (35–55)

42 ± 6 (29–55)

44 ± 7 (35–52)

45 ± 6 (35–55)

0.358